全文获取类型
收费全文 | 623686篇 |
免费 | 63309篇 |
国内免费 | 778篇 |
出版年
2018年 | 6706篇 |
2017年 | 6345篇 |
2016年 | 8631篇 |
2015年 | 10871篇 |
2014年 | 13167篇 |
2013年 | 18130篇 |
2012年 | 21361篇 |
2011年 | 22212篇 |
2010年 | 15017篇 |
2009年 | 13515篇 |
2008年 | 19573篇 |
2007年 | 20228篇 |
2006年 | 19126篇 |
2005年 | 18110篇 |
2004年 | 18271篇 |
2003年 | 17214篇 |
2002年 | 16856篇 |
2001年 | 25870篇 |
2000年 | 25614篇 |
1999年 | 20245篇 |
1998年 | 7341篇 |
1997年 | 7198篇 |
1996年 | 6824篇 |
1995年 | 6456篇 |
1994年 | 6180篇 |
1993年 | 6133篇 |
1992年 | 16625篇 |
1991年 | 16741篇 |
1990年 | 16498篇 |
1989年 | 15999篇 |
1988年 | 14843篇 |
1987年 | 14020篇 |
1986年 | 13238篇 |
1985年 | 13177篇 |
1984年 | 10804篇 |
1983年 | 9249篇 |
1982年 | 6798篇 |
1981年 | 6031篇 |
1980年 | 5736篇 |
1979年 | 10071篇 |
1978年 | 8065篇 |
1977年 | 7247篇 |
1976年 | 6852篇 |
1975年 | 8027篇 |
1974年 | 8793篇 |
1973年 | 8590篇 |
1972年 | 7712篇 |
1971年 | 7190篇 |
1970年 | 6096篇 |
1969年 | 6013篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
881.
In this study we construct a phylogenetic hypothesis for the relatedness among disjunct subspecies of Cyclamen repandum and its two allopatric congeners, C. creticum and C. balearicum in order to examine the evolutionary divergence of currently isolated populations across the western Mediterranean. The most
parsimonious phylogenetic tree obtained from sequencing the cpDNA trnL (UAA) intron suggests a major phylogeographic divide in southern Greece between two clades. The first clade comprises samples
of C. repandum subsp. peloponnesiacum (from the Peloponnese) and C. creticum (from Crete). The second comprises samples of C. repandum subsp. repandum (from Croatia, Italy, southern France, Corsica, Sardinia and Sicily), C. repandum subsp. rhodense (from Rhodes and Kos) and C. balearicum (from the Balearic Islands and southern France). These data suggest that C. creticum has evolved in allopatry from C. repandum subsp. peloponnesiacum and that C. balearicum and C. repandum ssp. rhodense have diverged from C. repandum subsp. repandum at its western and eastern distribution limits. At one small site on Corsica, a population of C. repandum may have introgressed with relictual populations of C. balearicum. These divergence patterns illustrate how a phylogenetic perspective can be used to better understand the evolution of endemism
in the Mediterranean flora.
Received February 19, 2001 Accepted August 22, 2001 相似文献
882.
F. Marsolat D. Tromson N. Tranchant P. Bergonzo F. Moignau L. De Carlan D. Lazaro M. Agelou C. Bassinet C. Huet S. Derreumaux M. Chea G. Boisserie I. Buchheit V. Marchesi 《Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)》2012
883.
S. J. Tzartos M. T. Cung P. Demange H. Loutrari A. Mamalaki M. Marraud I. Papadouli C. Sakarellos V. Tsikaris 《Molecular neurobiology》1991,5(1):1-29
Myasthenia gravis (MG) is caused by autoantibodies against the nicotinic acetylcholine receptor (AChR) of the neuromuscular junction. The anti-AChR antibodies are heterogeneous. However, a small region on the extracellular part of the AChR alpha subunit, called the main immunogenic region (MIR), seems to be the major target of the anti-AChR antibodies, but not of the specific T-cells, in experimental animals and possibly in MG patients. The major loop of the overlapping epitopes for all testable anti-MIR monoclonal antibodies (MAbs) was localized within residues 67-76 (WNPADYGGIK for Torpedo and WNPDDYGGVK for human AChR) of the alpha subunit. The N-terminal half of alpha 67-76 is the most critical, Asn68 and Asp71 being indispensable for binding. Yet anti-MIR antibodies are functionally and structurally quite heterogeneous. Anti-MIR MAbs do not affect channel gating, but they are very potent in mediating acceleration of AChR degradation (antigenic modulation) in cell cultures and in transferring experimental MG in animals. Fab fragments of anti-MIR MAbs bound to the AChR prevent the majority of the MG patients' antibodies from binding to and causing loss of the AChR. Whether this inhibition means that most MG antibodies bind on the same small region or is a result of broad steric/allosteric effects is under current investigation. 相似文献
884.
885.
Molecular determinants of visual pigment function. 总被引:1,自引:0,他引:1
M L Applebury 《Current opinion in neurobiology》1991,1(2):263-269
Mutagenesis studies and comparisons of natural variants of rhodopsin and related visual pigments have led to new insights concerning photoreceptor function. The studies identify domains important for receptor folding, the residues that set the wavelength of absorption for the ligand 11-cis retinal, and residues, that when mutated, trigger the cell death of photoreceptors. 相似文献
886.
887.
Léniz A. Portillo M. P. Fernández-Quintela Alfredo Macarulla M. T. Sarasua-Miranda A. del Hoyo M. Díez-López I. 《Journal of physiology and biochemistry》2019,75(3):311-319
Journal of Physiology and Biochemistry - Infants born small for gestational age (SGA) are at increased risk of perinatal morbidity, persistent short stature, and metabolic alterations in later... 相似文献
888.
889.
890.
Cefepime/amikacin in the empirical antibacterial therapy for patients with hemoblastosis of different forms] 总被引:1,自引:0,他引:1
The results of the use of cefepime (Maxipime) combination with amikacin vs ceftriaxon combination with amikacin in the treatment of 80 patients with different forms of hemoblastosis are presented. Severe infectious complications in the patients were associated with prolonged and deep neutropenia during inductive or antirelapsing chemotherapy. All the patients in the trial were from the group of high risk of infectious complications with the blood neutrophil count under 100 cells/microliter. The duration of neutropenia averaged 12 days (7 to 15). The average period of the treatment with cefepime and amikacin equaled to 13 days (8 to 16). The treatment with cefepime + amikacin was successful in 38 out of 40 patients (95%). The average period of the treatment with ceftriaxon and amikacin equaled to 14 days (7 to 18). The efficacy of the treatment with ceftriaxon + amikacin was 60% (24 patients out of 40). 相似文献